Background: The use of home parenteral nutrition (HPN) in incurable cancer patients is extremely varied across different countries and institutions. In order to assess the clinical impact implied, we previously conducted a survey of incurable cancer patients receiving HPN, which shows that survival was markedly affected by Karnofsky performance status (KPS), tumor spread, Glasgow prognostic score (GPS) and tumor site. The aim of this study was to develop a nomogram incorporating the above factors for survival prediction.
role toward personalized medicine and for investigating novel experimental therapies. Our proposed nomogram is a step forward in this direction but needs to be made stronger in order to definitely have clinical utility. Key words: cancer cachexia, home parenteral nutrition, incurable cancer patient, malignant obstruction, nomogram, survival prediction introduction The use of home parenteral nutrition (HPN) in incurable cancer patients is extremely varied across different countries and across different institutions within the same country. Several factors explain this situation. First of all, there is a divergence in the medical community between those who deem parenteral nutrition a medical therapy, the use of which must be supported by a rationale on a case-by-case basis, and those with a more liberal attitude who regard HPN as a commonly accepted supportive treatment. Secondly, the guidelines of both the European Society for Clinical Nutrition and Metabolism (ESPEN) [1] and those of the American Society for Parenteral and Enteral Nutrition (ASPEN) [2] are quite vague on this topic and indeed recommend relying on expert opinion. Last but not the least, there is a lack of robust data showing the survival outcome of incurable cancer patients on HPN, as well as on quality of life and on the risk/benefit ratio so as to inform clinical decisions. To at least partially overcome this shortcomings, we recently conducted a multicenter prospective study in a series of 414 incurable cachectic (sub)obstructed cancer patients receiving HPN [3] . The results we obtained showed that observed survival, on average exceeding that of aphagic patients without nutritional support [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , was markedly heterogeneous and could be explained by a number of prognostic characteristics like Karnofsky performance status (KPS), tumor spread, Glasgow prognostic score (GPS) and tumor site. Quite surprisingly, the study failed to show an independent prognostic significance of weight loss (WL). However, Martin et al. [14] meanwhile modeled the relationships for body mass index (BMI) and percent WL to overall survival (OS) and developed a robust grading system incorporating both. Capitalizing on the above work, in the study here presented we analyzed an extended database of 579 cancer patients undergoing HPN with the purpose of developing and validating a nomogram to predict survival.
patients and methods
The current investigation includes all the 414 patients who were the object of our previous study. Details on the study design and patients selection have been already published [3] . Briefly, the protocol and the case report form were conceived within the Home Artificial Nutrition-Chronic Intestinal Failure Working Group (HAN-CIF WG) of the European Society for Clinical Nutrition and Metabolism and distributed to the participating centers. Individual patient data had to be taken at patient's discharge from hospital and follow-up had to continue until death or for a minimum of 6 months, in case of longer survival.
Centers recommended HPN according to individual institutional policies without any interference by HAN-CIF WG, in compliance with the purposes of an observational study. The patient admission criteria were the following: adults/elderly patients with no or negligible oral/enteral nutrition (because of overt intestinal obstruction or sub-obstruction, intended as obstructive symptoms occurring only after an attempt to oral/enteral feeding, diagnosed on clinical/radiological ground and refractory to previous medical care), presence of an incurable malignancy and absence of any oncologic treatment, without major organ failure or major involvement of a vital organ or severe metabolic derangement. In addition, patients with ascites or pleural effusion (which might be exacerbated by the fluid infusion) and those with uncontrolled symptoms or those receiving HPN in the perspective to become candidate to a future oncologic treatment were excluded. It was required the prescription of an i.v. nutritional daily regimen including at least 25 kcal and 1 g amino acid/ kg bodyweight. Each center was granted permission to take part to the study from its own local Human Investigations Committee.
After that, a new mono-institutional prospective series was made available by one of the authors (PC). The corresponding database included 432 records overall, but for the aims of the present investigation we retained only records of the 165 patients fulfilling the selection criteria previously described. As a result, the overall series included data from 579 patients recruited by 14 centers and receiving HPN between November 2004 and March 2011.
As detailed in Supplementary Appendix S1, available at Annals of Oncology online, a part of the data (training sample) was used to fit a multivariable Cox proportional hazards regression model and building a nomogram for estimating median, 3-and 6-month OS using tumor spread, GPS, KPS and tumor site as predictors. Performance of the nomogram was assessed in the remaining testing sample.
results
Patient and disease characteristics are shown in Table 1 for the overall series as well as for the training and testing samples separately. Median age was 64 years, males were moderately prevalent (54.8%) and median KPS was 60. Median BMI and WL were 20% and 13.8%, respectively. The resulting distribution of BMI-adjusted WL covered the whole range allowed between 0 and 4; however, about two-thirds of cases (66.1%) were grade 4, a quarter (25.1%) were grade 3 and the few cases remaining (8.8%) were scattered among grade 0-2. Moreover, the median of C-reactive protein (CRP) was 9.25 mg/l. Such data confirm that, as expected, our patients were severely malnourished and could be defined as cachectic according to the current definitions. Among tumor characteristics, most patients (66.2%) had metastatic disease.
Training and testing samples were well matched on all the characteristics investigated.
Supplementary Figure S1 , available at Annals of Oncology online, shows that the corresponding Kaplan-Meier survival curves were overlapping, median survival (95% confidence interval) being equal to 3.2 (3.0-3.7) months in the training sample and 3.3 (2.9-3.9) months in the testing sample.
BMI-adjusted WL was entered into the multivariable regression analysis as a three-level categorical variable, having gathered grades from 0 to 2 into a single class in order to avoid sparse data. Even so, a very high P value was obtained (P = 0.8223), and this factor was therefore disregarded for the construction of the nomogram. In the absence of interaction terms, significant results were obtained for all the remaining factors, tumor site included (P = 0.0402). Optimal categorization of the latter distinguished between ovary, gastro-intestinal (GI, including upper and lower GI and pancreas) and 'other' locations. Following the achievement of a significant overall test of interaction (23 degrees of freedom, P = 0.0472), AIC-based backward selection lead to retain a single interaction, that between tumor site and spread. As a result of the above-described processing, the final multivariable Cox regression model was fit including the factors shown in Table 2 , namely GPS, KPS, tumor site and spread. Hazard ratio estimates greater than one indicate that higher mortality was associated with increasing GPS and KPS ≤ 50. The effects of tumor site and spread must be interpreted taking into account the presence of an interaction between these two factors. By summarizing the HR figures shown in Table 2 , it is possible to state that the presence of disease metastases was in general associated with higher mortality, this association being strong, however, only for tumors with 'other' site. Conversely, tumor site was almost not influential in localized disease, while in the presence of metastases the worst outcome was observed for tumors with 'other' location. The nomogram obtained from the above Cox model (Figure 1 ) was built in order to estimate median survival or survival probability at 3 and 6 months according to individual patient characteristics. Projection of nomogram predictions on the testing sample yielded satisfactory results. The calibration plot shown in Supplementary Figure S2 , available at Annals of Oncology online, compares observed survival (vertical axis) toward predicted survival (horizontal axis) considering both 3-and 6-month estimates. The agreement between predicted and observed survival was good, as suggested by closeness of the represented points to the reference line of ideally perfect agreement. At an individual level, the scatter of observed survival around nomogram prediction was relatively high, as shown in Supplementary Figure S3 , available at Annals of Oncology online. Nevertheless, regarding discrimination ability, the 3-and 6-month time-dependent AUC-ROC estimates were 0.635 (SE = 0.003) and 0.714 (SE = 0.003), respectively.
With this nomogram, the category of each prognostic factor is assigned a score using the topmost 'Points' scale, then a sum is calculated across all patient characteristics so as to obtain the 'Total points' that are eventually converted into the desired statistics. Notably, higher total points correspond to worse prognosis. As an illustrative example, we suppose a patient with the following characteristics: GPS = 2, non-metastatic cancer at the ovary, and KPS ≤ 50. By locating each of these characteristics on the corresponding scale and drawing a vertical straight line up to the Points scale, we obtain the scores of around 90, 5 and 80, respectively, which add up to 175. Locating this value on the total points scale and drawing a straight line from this point to the downward scales, the total score of 175 may be converted into the following predictions: median survival close to 2.5 months; estimated 3-and 6-month survival probabilities of around 40% and 10%, respectively. usually due to the presence of a malignant (sub)obstruction, is of only a few weeks in the absence of nutritional support [15, 16] . Our series of patients on HPN, mostly belonging to class III-IV of the BMI-adjusted WL according to Martin et al. [14] , had a median survival slightly exceeding 3 months, as already shown in our previous investigation [3] . This is an expected finding for advanced cachectic cancer patients who only receive palliative care support.
Building on previous identification of GPS, KPS, tumor site and spread as significant prognostic factors in this patient population, we incorporated these factors into the construction of a nomogram enabling estimation of expected survival in terms of either median time or 3-and 6-month survival probability, taking into account the combination of individual characteristics on a case-by-case basis. Noteworthy, these characteristics are commonly assessed in routine clinical practice, both in hospitalized and ambulatory patients, which is clearly a practical advantage.
Survival under HPN is quite varied, ranging from a few weeks in patients with bad scores (e.g. in case of non-ovarian metastatic tumors with GPS > 2 and KPS ≤ 50) to almost 2 years in most favorable cases (e.g. ovary cancer patients with low GPS and good KPS). Health professionals may thus utilize this nomogram to easily estimate the expected survival whenever the interest lies in the construction of prognostically homogeneous subgroups, for instance the selection of patients with limited survival, this being a criterion of inclusion in a clinical trial. A strong justification to nomogram use may be represented by ESPEN guidelines, considering the use of HPN indicated in incurable aphagic cancer patients whenever expected survival is of 2-3 months at least. Such a recommendation relies on the acknowledgement that, even in healthy conditions, fasting people die within this time span [7, 8] . However, we do not recommend to use the nomogram rigidly because of uncertainty of individual predictions and relevance of the quality of life issue. Actually, when a hypothetically incurable and aphagic patient is offered the option of receiving parenteral nutrition without any further attempt of an oncologic approach, a balance needs to be done between the expected gain in survival and quality of the remaining life. Literature data on the quality of life of cancer patients receiving HPN are rather scarce and focus on outcomes observed after only 1 month of HPN [17, 18] . Another recent paper [19] reported a statistically significant improvement in global quality of life, subjective global assessment, body weight and KPS from baseline after 3 months, but the patients were receiving a concurrent chemotherapy and no mention was made on whether the benefit was confounded by better tumor control. In a longterm study on incurable cancer patients, we previously reported that quality of life in cancer patients on HPN remained substantially stable till 2-3 months before death [20] . Hence, by combining information on current patient status and prognostic patient characteristics, the task of making this balance is facilitated on both the sides of health professionals and that of patients or their relatives by using the proposed nomogram.
Byproducts of this study were a more careful investigation of the joint role of tumor site and spread as well as exploration of the BMI-adjusted WL. Regarding the first aspect, we observed that tumor site was influential in case of metastatic disease, covering around two-thirds of the overall series, and that ovarian cancer patients in particular tended to have longer survival.
In contrast, we failed to show a significant prognostic effect of BMI-adjusted WL. This finding may be largely explained by the uneven distribution of this factor in our series, mostly concentrated in class III and IV, and in itself does not invalidate the importance of BMI-adjusted WL in the broad population of oncologic patients, according to the results obtained by Martin et al. [14] .
The strength of the present study was the multicenter gathering of the series and its relatively large size, which enabled us to implement a split-sampling approach in order to validate statistical results. However, there are some limitations to be acknowledged. In particular, we controlled prospectively the outcome of the patients but we were unable to get details on either qualitative or quantitative composition of nutritional admixtures at the start of HPN or about compliance to the prescribed HPN schedule. Actually, research is ongoing to define the best nutritional support of advanced cancer patients and future patients will likely benefit of an optimized regimen including a high fat/ glucose ratio [21] and high quality amino acids [22] .
The list of covariates considered for nomogram construction was bounded by the study that we previously conducted [3] . However, it is reasonable to assume that other factors might be prognostic, like those possibly predicting organ failure or thromboembolic events, which are not infrequent causes of sudden death in advanced cancer patients. A push to explore other variables may be also motivated by the finding of a large amount of residual variation, as emphasized by the rather unsatisfying c-statistics reported above for our final model.
A further limitation was the absence of information on quality-of-life experience. However, by considering that only a small minority of patients (N = 29, 5.0%) withdrew from HPN because of no benefit perceived by patients themselves or their relatives, it is possible to infer that quality of life was generally acceptable. In our opinion, the above limitations do not obscure importance of having investigated a neglected and controversial palliative care area like that of supportive use of nutrition in incurable cancer patients. HPN is expected to become increasingly common in parallel with the growing availability of new oncologic treatments and their tendency to transform the trajectory of the advanced cancer into a chronic condition. In such a scenario, progressive WL and undernutrition are an always more frequent condition, which finally accounts for major debilitation and early mortality. Within this setting, tools for predicting the survival outcome may play a role toward personalized medicine as well as for clinical trials design, as far as interest will arise in identifying long-term survivors on HPN suitable for investigating novel experimental therapies. Our proposed nomogram is a step forward in this direction but needs to be further improved with the inclusion of additional predictors, in order to be strong enough and definitely have clinical utility. 
